Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome
Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
This is a prospective cohort study to observe the efficacy and safety of Tofacitinib in children with Blau syndrome (BS). The investigators would analyze the rate of remission or low disease activity after treatment as well as changes in inflammatory markers, patients' and physician's global assessment of disease activity to determine the efficacy and safety of Tofacitinib.